INCORPORATION OF INFORMATION BY REFERENCE
The SEC allows us to incorporate by reference information into this prospectus supplement, which means that we can disclose important information
to you by referring you to another document filed separately with the SEC. The information incorporated by reference is deemed to be a part of this prospectus supplement, except for any information superseded by information in any amendment to this
prospectus supplement.
The following documents filed with the SEC are incorporated by reference in this Registration Statement:
(a) The Companys Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Commission on March 15,
2023, and the amendment thereto, filed with the Commission on April 24, 2023.
(b) The Companys Quarterly Reports on Form 10-Q (i) for the quarter ended March 31,
2023, filed with the Commission on May 10, 2023; and (ii) for the quarter ended June 30, 2023, filed
with the Commission on August 9, 2023.
(c) The Companys Current Reports on Form 8-K filed on January 23,
2023, January
24, 2023, January
30, 2023 (as amended on April
10, 2023), February
7, 2023, March
7, 2023, March
15, 2023, March
31, 2023, May
9, 2023, May
10, 2023, May
30, 2023, June
1, 2023, June
23, 2023, July
21, 2023, July
28, 2023, August
9, 2023 and August 25, 2023.
(d) The description of the Common Shares filed with the Commission on Form
8-A12B on September 29, 2006, as amended on October 18, 2006.
All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of
1934, as amended (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this
Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be
incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be
deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes
such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
You may obtain a copy of any of these documents at no cost by requesting them from us or by writing or calling: Catalyst Pharmaceuticals, Inc., 355 Alhambra
Circle, Suite 801, Coral Gables, Florida, 33134, Attn: Investor Relations, or by calling (305) 420-3200. Copies of each of these filings are also available for no cost on our website,
www.catalystpharma.com, or on the SECs web site, www.sec.gov.
DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION
FOR SECURITIES ACT LIABILITIES
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the registrant
pursuant to the foregoing provisions, the registrant has been informed that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.
23